Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer

Journal of Clinical Oncology

Volumn 33, Issue 14, 2015, Pages 1521-1522

  Zsiros, Emese ^a   Tsuji, Takemasa ^a   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE T CELL THERAPY; ADOPTIVE TRANSFER; ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); EDITORIAL; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECURRENT METASTATIC CERVICAL CANCER; SALVAGE THERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; ALPHAPAPILLOMAVIRUS; CYTOTOXIC T LYMPHOCYTE; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS;

EID: 84933564607     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.6566     Document Type: Editorial

References (13)

1. Tewari KS, Sill MW, Long HJ 3rd, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734-743, 2014
2. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19, 1999
3. Stern PL, van der Burg SH, Hampson IN, et al: Therapy of human papillomavirus-related disease. Vaccine 30:F71-F82, 2012 (suppl 5)
4. Stevanović S, Draper LM, Langhan MM, et al: Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33:1543-1550, 2015
5. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002
6. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357, 2005
7. Cho HI, Reyes-Vargas E, Delgado JC, et al: A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res 72:1986-1995, 2012
8. Gilham DE: Effective adoptive T-cell therapy for cancer in the absence of host lymphodepletion. Immunotherapy 3:177-179, 2011
9. Napoletano C, Bellati F, Tarquini E, et al: MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 198:99.e1-e7, 2008
10. Lawrence MS, Stojanov P, Polak P, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214-218, 2013
11. Dudley ME, Wunderlich JR, Shelton TE, et al: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342, 2003
12. Dudley ME, Yang JC, Sherry R, et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239, 2008
13. Park TS, Rosenberg SA, Morgan RA: Treating cancer with genetically engineered T cells. Trends Biotechnol 29:550-557, 2011